Is There a Generic Wegovy?
Cheapest legitimate alternatives to Wegovy in 2026
| Alternative | Monthly |
|---|---|
| Foundayo (orforglipron) | $149 |
| Oral Wegovy 25 mg (NovoCare) | $149 |
| Novo subscription via Hims/Ro/LifeMD (12-month plan) | $249 |
| Zepbound (tirzepatide) starter | $299 |
| Wegovy injection (NovoCare standard) | $349 |
| Wegovy cash retail (full WAC) | $1,349 |
Every monthly number above is the same one used by our calculator and traces to a manufacturer or telehealth public pricing page. The Novo subscription row is the manufacturer-set partner-program tier for Wegovy injection via Hims, Ro, LifeMD, WeightWatchers, or Sesame; see /how-much-does-wegovy-cost for the full channel breakdown.
Why no generic Wegovy exists in 2026
1. Patent protection. Novo Nordisk holds active US patents on semaglutide (composition-of-matter and the 2.4 mg formulation specific to Wegovy) that extend into the early 2030s. While a patent is in force, no other manufacturer can market the same molecule without licensing it.
2. Biologic complexity. Semaglutide is a peptide drug. When peptide patents expire, the path to market for competitors is the FDA biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), not the traditional Hatch-Waxman generic pathway. Biosimilar approval requires demonstrating "no clinically meaningful differences" through head-to-head clinical studies - much more expensive and time-consuming than developing a small-molecule generic.
3. Realistic timing. Composition-of-matter patent expiration in the early 2030s + biosimilar approval lead time of 3-5 years = realistic biosimilar semaglutide on the US market in the 2031-2035 window. The cost pressure on Wegovy in the meantime comes from competitive launches (Foundayo April 2026, CagriSema pending, retatrutide phase 3) and Novo Nordisk's own subscription program (March 2026), not from biosimilars.
Frequently asked questions
Is there a generic version of Wegovy?
No. As of May 2026, there is no FDA-approved generic version of Wegovy (semaglutide 2.4 mg injection) on the US market. Wegovy is still under patent protection by Novo Nordisk, and the additional fact that semaglutide is a peptide drug, not a small molecule, means even after patent expiration the path is a biosimilar (which has its own FDA approval pathway) rather than a traditional generic.
What is the generic name for Wegovy?
Wegovy is the brand name; the active ingredient is semaglutide. Semaglutide is also the active ingredient in Ozempic (FDA-approved for type 2 diabetes), Rybelsus (oral, T2D), and the newer Wegovy oral 25 mg tablet (FDA-approved for weight management in January 2026). "Generic Wegovy" as a marketed product does not exist in 2026, but the molecule name semaglutide is what you would look for if and when a biosimilar arrives.
When will Wegovy go generic?
Semaglutide composition-of-matter patents extend into the early 2030s in the US, with formulation, manufacturing-process, and indication patents extending further. Biosimilar competitors typically need patent expiration plus several years of FDA biosimilar approval process. Realistic timing: biosimilar semaglutide on the US market is most likely a 2031–2035 event, not a 2026–2027 event. The earlier price-pressure mechanism is competitive launches (Foundayo / orforglipron approved April 2026 at $149/month, CagriSema and retatrutide pending) rather than biosimilars.
Why is there no generic Wegovy yet?
Two reasons. (1) Patent protection: Novo Nordisk holds an active US patent on semaglutide that does not expire until the early 2030s. Under US patent law, no other manufacturer can market the same molecule without licensing it. (2) Biologic complexity: even after patent expiration, semaglutide is a peptide drug, which the FDA classifies under the biologic pathway (BPCIA), not the traditional Hatch-Waxman generic pathway. Biosimilar approval requires demonstrating "no clinically meaningful differences" through additional clinical studies, which takes years longer than a small-molecule generic and is much more expensive to develop.
What is the cheapest legitimate alternative to Wegovy in 2026?
Three cheapest paths in May 2026: (1) Foundayo (orforglipron) at LillyDirect, $149/month for the 0.8 mg lowest dose - same molecule class (GLP-1 receptor agonist), different molecule (non-peptide), FDA-approved April 2026. (2) Oral Wegovy 25 mg at NovoCare, $149/month for the 1.5 mg and 4 mg titration doses (the 4 mg discount runs through Aug 31, 2026). Same molecule as injection Wegovy, in tablet form. (3) The Novo Nordisk subscription program for Wegovy injection at $249/month on a 12-month plan via Hims, Ro, LifeMD, WeightWatchers, or Sesame. All three are legitimate, branded, FDA-approved cash-pay paths under $250/month.
What about compounded semaglutide?
Compounded semaglutide is a non-FDA-approved version manufactured by 503A or 503B compounding pharmacies, historically priced around $199/month via telehealth. Legal status narrowed sharply in 2025-2026: the FDA ended enforcement discretion for 503B (March 2025) and 503A (February 2025) once the official semaglutide shortage was declared resolved. On April 30, 2026, the FDA proposed adding semaglutide to the 503B Bulks List exclusion. 503A retains a narrow individual-patient exception for documented allergy or specific clinical justification; cost savings alone does not qualify. Hims, Ro, and other major telehealth platforms have largely shifted to branded drugs. Compounded semaglutide is not a generic Wegovy; it is a different regulatory category, and as of 2026 it is not the cheap-and-easy option it was in 2023.
Is Ozempic the generic Wegovy?
No, but it is the same molecule. Both Ozempic and Wegovy contain semaglutide as the active ingredient. Ozempic is FDA-approved for type 2 diabetes (and cardiovascular risk reduction in T2D); Wegovy is FDA-approved for chronic weight management. The molecule is identical, but the FDA indications and dosing are different (Wegovy goes up to 2.4 mg, Ozempic up to 2.0 mg). If you have type 2 diabetes, insurance is much more likely to cover Ozempic. If you do not, insurance will typically deny Ozempic and Wegovy is the path. They are sister drugs, not brand-vs-generic.
Is semaglutide cheaper than Wegovy?
Semaglutide is the molecule, so "semaglutide" in 2026 means one of three branded products: Wegovy (weight-loss indication, $1349/month list, $349/month NovoCare self-pay), Ozempic (T2D indication, $998/month list), or oral Wegovy 25 mg tablet (weight-loss indication, $149/month NovoCare self-pay). The cheapest branded semaglutide path is oral Wegovy 25 mg at $149/month for the lower titration doses through NovoCare. Compounded semaglutide is no longer a reliable cheaper path (see above). There is no over-the-counter or non-branded "semaglutide" you can purchase legally in 2026.
What about non-semaglutide GLP-1 alternatives?
Three to consider, all FDA-approved and substantially different molecules. (1) Foundayo (orforglipron), a daily oral non-peptide GLP-1, $149/month lowest dose at LillyDirect, 14.7% weight loss in ATTAIN-1 (vs Wegovy's 14.9% in STEP-1). (2) Zepbound (tirzepatide), a once-weekly dual GIP/GLP-1, $299/month starter dose at LillyDirect, 22.5% peak weight loss in SURMOUNT-1 (highest efficacy of any approved GLP-1). (3) Saxenda (liraglutide), an older daily injection - same list price as Wegovy but much lower efficacy (8.4% in SCALE) and rarely the right choice in 2026 unless insurance specifically prefers it.
Does the Wegovy patent expire soon?
Not soon enough to drive prices in 2026 or 2027. Semaglutide composition-of-matter patents extend into the early 2030s in the US, with additional patents on the 2.4 mg formulation, manufacturing process, and weight-management indication extending further. Even after key patents expire, the biosimilar (not generic) approval pathway under BPCIA typically adds 3-5 years before a competitor reaches market. Realistic biosimilar semaglutide arrival in the US: 2031-2035 window. In the meantime, the cost-pressure mechanism is competitive launches (Foundayo, CagriSema, retatrutide) and manufacturer direct programs (NovoCare, the Novo subscription via partner telehealth) - not biosimilars.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.